由 John R. Fischer
, Senior Reporter | October 23, 2020
iCAD’s ProFound AI solution for digital breast tomosynthesis will now be distributed as a part of Change Healthcare’s Mammography Plus solution.
The addition of ProFound AI is expected to enhance the workflow offerings of Change Healthcare’s mammography software solution with its deep learning AI capabilities. In exchange, integration with Mammography Plus expands access to ProFound AI among hospitals and imaging centers in North America.
"ProFound AI provides valuable information about the location and certainty of suspicious findings, indicating the algorithm's confidence that a finding or case is malignant," Stacey Stevens, president of iCAD Medical, told HCB News. "This information can be used by the Change Healthcare Mammography Plus system to help the radiologist determine exam reading order, highlight and quickly navigate to the most suspicious findings and create an optimal and efficient reading experience for radiologists."
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs
A single platform for radiology PACS and mammography, Mammography Plus is equipped with advanced workflow capabilities to help clinicians interpreting full-field digital mammography and digital breast tomosynthesis. It enables fewer clicks and automates tasks to eliminate duplicate actions.
ProFound AI is designed to quickly assess and identify malignant lesions on individual images for radiologists reviewing mammograms or DBT scans, and provides a two-year breast cancer risk estimation that is personalized for each woman. The solution has been trained on 3D image datasets and will provide radiologists using Mammography Plus with observations such as certainty of finding lesion and case scores to assist them in making decisions and prioritizing cases.
A recent study
conducted at Karolinska University in Sweden rated ProFound AI as highly accurate with an area under the curve (AUC) of 0.73, and superior in its performance compared to existing risk models at two years, including for breast density within their calculations.
"More doctors and patients in the U.S. and Canada will benefit from ProFound AI for 3D mammography because of this collaboration, resulting in earlier breast cancer detection," said Stevens.